Biomarkers for First-Onset Psychosis
Author Information
Author(s): Huang Jeffrey T.-J, Leweke F. Markus, Oxley David, Wang Lan, Harris Nathan, Koethe Dagmar, Gerth Christoph W, Nolden Brit M, Gross Sonja, Schreiber Daniela, Reed Benjamin, Bahn Sabine
Primary Institution: Institute of Biotechnology, University of Cambridge
Hypothesis
Can cerebrospinal fluid biomarkers differentiate between patients with first-onset psychosis and healthy individuals?
Conclusion
The study found significant differences in cerebrospinal fluid protein profiles between patients with first-onset paranoid schizophrenia and healthy controls, suggesting potential biomarkers for early diagnosis.
Supporting Evidence
- Patients with first-onset paranoid schizophrenia showed a 2.8-fold elevation of a specific peptide compared to controls.
- Key protein changes were replicated in an independent sample set.
- The study achieved a specificity of 95% and sensitivity of 80% or 88% in different experiments.
Takeaway
Doctors can look for special proteins in the fluid around the brain to help tell if someone has a serious mental illness like schizophrenia.
Methodology
The study used surface-enhanced laser desorption ionization mass spectrometry to analyze cerebrospinal fluid samples from patients and controls.
Limitations
The study did not include samples from patients with non-schizophrenia psychosis, limiting the ability to draw broader conclusions.
Participant Demographics
The study included 58 drug-naïve schizophrenia patients, 16 patients with depression, 5 with OCD, 10 with Alzheimer disease, and 90 healthy controls.
Statistical Information
P-Value
10−8
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website